Vistin Pharma Q2 2025 slides: Revenue up 11%, sales volume surges 17%

Vistin Pharma ASA reported robust Q2 2025 results, with revenue increasing 11% to MNOK 118 and EBITDA up 11% to MNOK 30, primarily driven by a 17% rise in sales volume. As a pure-play metformin producer holding approximately 10% of the global market, the company is well-positioned to capitalize on the expanding global diabetes market, projected to grow significantly by 2050. Despite a modest increase in net debt due to a dividend payment, Vistin maintains a strong 70% equity ratio and stable 26% EBITDA margins, underpinned by its strategic European manufacturing advantage and long-term renewable energy supply.

Analysis

Vistin Pharma ASA (OB:VISTN) reported strong Q2 2025 results, underscoring its solid position in the global metformin market. Revenue grew 11% year-over-year to MNOK 118, driven by a notable 17% increase in sales volume, which indicates robust underlying demand rather than price inflation. Profitability remained high and stable, with EBITDA also increasing 11% to MNOK 30, maintaining a consistent 26% EBITDA margin and a 63% gross margin despite noted raw material transportation challenges. The company's strategic positioning as a European-based manufacturer with approximately 10% of the global market share is a key advantage, especially as it capitalizes on a secular growth trend in diabetes diagnoses, projected to expand the market by 4-6% annually. While net debt increased to MNOK 40, this was primarily a function of a MNOK 55 dividend payment and higher working capital needs to support growth, and the balance sheet remains robust with a 70% equity ratio. The long-term renewable energy agreement with Statkraft further strengthens its ESG profile and provides cost predictability, a significant competitive advantage.

Key Decisions for Investors

• Given the consistent volume-led growth and stable high margins, investors should view Vistin Pharma as a strong operator capitalizing on a durable, long-term health trend, supporting a fundamentally bullish thesis.
• Monitor working capital dynamics, specifically the longer payment times from Asian customers, though the recent rise in net debt should be contextualized by the significant dividend payout and growth-related investments.
• The company's European manufacturing base and strong ESG credentials, including a long-term green energy contract, should be considered a key strategic asset that could mitigate geopolitical supply chain risks and attract a valuation premium.